China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. reports an increase in revenue and net profit for its subsidiary, Dong-E-E-Jiao, in the first half of 2024, with a proposed dividend distribution awaiting shareholder approval. Despite a decrease in total and net assets, the company’s earnings and net cash flow from operating activities have significantly risen. Investors are cautioned that these unaudited financials are not fully representative of the group’s overall performance and should exercise care when dealing in the company’s securities.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
